CompletedPhase 2NCT00204633
Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
Studying Malignant germ cell tumor of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital Tuebingen
- Principal Investigator
- Joerg T. Hartmann, MDSouth West German Cancer Center, Medical Center II, University of Tuebingen
- Intervention
- Darbepoetin alfa(drug)
- Enrollment
- 108 enrolled
- Eligibility
- 18-65 years · MALE
- Timeline
- 2003 – 2008
Study locations (1)
- Medical Center II, University of Tuebingen, Tübingen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00204633 on ClinicalTrials.govOther trials for Malignant germ cell tumor of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04804007Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCTNabil Adra
- RECRUITINGPHASE1NCT04038619Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsM.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT02830724Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersNational Cancer Institute (NCI)